BACKGROUND: Persons with HIV infection have been reported to develop age-related diseases at younger ages than those without HIV. Whether this finding is related to HIV infection or failure to control for other risk factors is unknown. OBJECTIVE: To investigate whether persons with HIV infection develop hepatitis C virus (HCV)-related liver disease at younger ages than similar persons without HIV. DESIGN: Comparison of the severity of liver fibrosis by age among persons who have HCV with and without HIV followed concurrently in the same protocol. SETTING: Observational cohort from Baltimore, Maryland, participating in the ALIVE (AIDS Linked to the IntraVenous Experience) study. PARTICIPANTS: 1176 current and former injection drug users with antibodies to HCV. MEASUREMENTS: Liver fibrosis assessed semiannually from 2006 to 2011 by elastography (FibroScan, Echosens, Paris, France) and using previously validated thresholds for clinically significant fibrosis and cirrhosis; concurrent assessment of medical history, alcohol and illicit drug use, HCV RNA levels, hepatitis B virus surface antigen level, body mass index, and (for those with HIV) CD4+ lymphocyte count and HIV RNA levels. RESULTS: Among 1176 participants with antibodies to HCV, the median age was 49 years and 34% were coinfected with HIV and HCV. Participants contributed 5634 valid liver fibrosis measurements. The prevalence of clinically significant fibrosis without cirrhosis (12.9% vs. 9.5%) and of cirrhosis (19.5% vs. 11.0%) was greater in persons coinfected with HIV and HCV than in those with only HCV (P < 0.001). Increasing age and HIV infection were independently associated with liver fibrosis, as were daily alcohol use, chronic hepatitis B virus infection, body mass index greater than 25 kg/m2, and greater plasma HCV RNA levels. When these factors were kept constant, persons with HIV had liver fibrosis measurements equal to those of persons without HIV, who were, on average, 9.2 years older. LIMITATION: The process of liver fibrosis began before the study in most persons. CONCLUSION: In this cohort, persons who have HCV with HIV have liver fibrosis stages similar to those without HIV who are nearly a decade older. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse.
BACKGROUND:Persons with HIV infection have been reported to develop age-related diseases at younger ages than those without HIV. Whether this finding is related to HIV infection or failure to control for other risk factors is unknown. OBJECTIVE: To investigate whether persons with HIV infection develop hepatitis C virus (HCV)-related liver disease at younger ages than similar persons without HIV. DESIGN: Comparison of the severity of liver fibrosis by age among persons who have HCV with and without HIV followed concurrently in the same protocol. SETTING: Observational cohort from Baltimore, Maryland, participating in the ALIVE (AIDS Linked to the IntraVenous Experience) study. PARTICIPANTS: 1176 current and former injection drug users with antibodies to HCV. MEASUREMENTS: Liver fibrosis assessed semiannually from 2006 to 2011 by elastography (FibroScan, Echosens, Paris, France) and using previously validated thresholds for clinically significant fibrosis and cirrhosis; concurrent assessment of medical history, alcohol and illicit drug use, HCV RNA levels, hepatitis B virus surface antigen level, body mass index, and (for those with HIV) CD4+ lymphocyte count and HIV RNA levels. RESULTS: Among 1176 participants with antibodies to HCV, the median age was 49 years and 34% were coinfected with HIV and HCV. Participants contributed 5634 valid liver fibrosis measurements. The prevalence of clinically significant fibrosis without cirrhosis (12.9% vs. 9.5%) and of cirrhosis (19.5% vs. 11.0%) was greater in persons coinfected with HIV and HCV than in those with only HCV (P < 0.001). Increasing age and HIV infection were independently associated with liver fibrosis, as were daily alcohol use, chronic hepatitis B virus infection, body mass index greater than 25 kg/m2, and greater plasma HCV RNA levels. When these factors were kept constant, persons with HIV had liver fibrosis measurements equal to those of persons without HIV, who were, on average, 9.2 years older. LIMITATION: The process of liver fibrosis began before the study in most persons. CONCLUSION: In this cohort, persons who have HCV with HIV have liver fibrosis stages similar to those without HIV who are nearly a decade older. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse.
Authors: Mathias Lichterfeld; Danlei Mou; Thai Duong Hong Cung; Katie L Williams; Michael T Waring; Jinghe Huang; Florencia Pereyra; Alicja Trocha; Gordon J Freeman; Eric S Rosenberg; Bruce D Walker; Xu G Yu Journal: Blood Date: 2008-08-26 Impact factor: 22.113
Authors: Pierre Pradat; Nicolas Voirin; Hans Ludger Tillmann; Michèle Chevallier; Christian Trépo Journal: Liver Int Date: 2007-04 Impact factor: 5.828
Authors: Gregory D Kirk; Jacquie Astemborski; Shruti H Mehta; Chuck Spoler; Cedric Fisher; Danisha Allen; Yvonne Higgins; Richard D Moore; Nezem Afdhal; Michael Torbenson; Mark Sulkowski; David L Thomas Journal: Clin Infect Dis Date: 2009-04-01 Impact factor: 9.079
Authors: Brian J McMahon; Dana Bruden; Michael G Bruce; Stephen Livingston; Carol Christensen; Chriss Homan; Thomas W Hennessy; James Williams; Daniel Sullivan; Hugo R Rosen; David Gretch Journal: Gastroenterology Date: 2009-11-10 Impact factor: 22.682
Authors: Matthew Hoare; William T H Gelson; Abhi Das; Jean M Fletcher; Susan E Davies; Martin D Curran; Sarah L Vowler; Mala K Maini; Arne N Akbar; Graeme J M Alexander Journal: J Hepatol Date: 2010-04-22 Impact factor: 25.083
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Risha Irvin; Geetanjali Chander; Kathleen M Ward; Sean Manogue; Oluwaseun Falade-Nwulia; Juhi Moon; Catherine G Sutcliffe; Sherilyn Brinkley; Taryn Haselhuhn; Stephanie Katz; Kayla Herne; Lilian Arteaga; David L Thomas; Shruti H Mehta; Mark S Sulkowski Journal: J Viral Hepat Date: 2020-01-07 Impact factor: 3.728
Authors: Oluwaseun Falade-Nwulia; Risha Irvin; Alana Merkow; Mark Sulkowski; Alexander Niculescu; Yngvild Olsen; Kenneth Stoller; David L Thomas; Carl Latkin; Shruti H Mehta Journal: J Subst Abuse Treat Date: 2019-01-30
Authors: Tanyaporn Wansom; Oluwaseun Falade-Nwulia; Catherine G Sutcliffe; Shruti H Mehta; Richard D Moore; David L Thomas; Mark S Sulkowski Journal: Open Forum Infect Dis Date: 2017-02-11 Impact factor: 3.835
Authors: Meredith Greene; Kenneth Covinsky; Jacquie Astemborski; Damani A Piggott; Todd Brown; Sean Leng; Noya Galai; Shruti H Mehta; Jack Guralnik; Kushang V Patel; Gregory D Kirk Journal: AIDS Date: 2014-11-28 Impact factor: 4.177